



Technical Report No. 39 (Revised 2021)

**Guidance for Temperature-Controlled
Medicinal Products — Maintaining the Quality of
Temperature-Sensitive Medicinal Products through the
Transportation Environment**

Guidance for Temperature-Controlled Medicinal Products — Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment Team

Authors and Contributors

Chris J. Anderson, Cardinal Health

Rafik H. Bishara, Ph.D., RHB Technical Advising, LLC (Co-Chair)

Volker Cloos, Eli Lilly

Giovanni Curotto, veryQ pharma AG

Fabian De Paoli, GSK

Jean-Pierre Emond, Ph.D., The Illuminate Group

Michael English, Merck

Paul Harber, Parenteral Supply Chain, LLC

Nina Heinz, DHL

Zvonimir Majic, Ph.D., Teva

Mark Maurice, Sensitech (Co-Chair)

Janusz Mielewczyk, Amgen

Jahanvi Miller, MBA, PDA

Anthony (TJ) Rizzo, Cold Chain Technologies

Robert Seevers, Ph.D., Pearl Pathways

Dan Sorgen, Genentech

Joe Swigunski, Kite Pharma a Gilead Company

Cynthia Travaglini, UCB

Erik J. van Asselt, Ph.D., Merck, Sharp, & Dohme

Brian Wallin, Kite Pharma a Gilead Company

Guidance for Temperature- Controlled Medicinal Products — Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment

Technical Report No. 39 (Revised 2021)

ISBN: 978-1-945584-29-9

© 2021 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	5.4 Stakeholder Management.....	13
1.1 Purpose.....	1	5.5 Management of Nonconformances	14
1.2 Scope	1	5.5.1 Categorization of Nonconformances	14
2.0 GLOSSARY	2	5.5.2 Impact Assessment	14
2.1 Abbreviations.....	5	5.5.3 Corrective and Preventive Actions (CAPA)....	15
3.0 PROCESS DESIGN	6	5.5.4 Product Control and Disposition Decision....	15
3.1 User Requirements Specification (URS)	6	5.5.5 Approval and Closure	15
3.2 Quality Risk Assessment.....	6	5.6 Complaints.....	16
3.3 Design Qualification (DQ)	6	5.7 Periodic Review.....	16
4.0 PROCESS QUALIFICATION	8	5.8 Change Control.....	16
4.1 Operational Qualification (OQ)	9	6.0 CONCLUSION	17
4.2 Performance Qualification (PQ).....	10	7.0 REFERENCES	17
4.3 Qualification Plan Complete.....	10	8.0 CASE STUDIES.....	18
4.4 Shipping Control Strategy	11	8.1 Case Study 1: Distribution Incident	
5.0 ONGOING PROCESS VERIFICATION.....	11	Trends Analysis.....	18
5.1 Standard Operating Procedures (SOP)	12	8.2 Case Study 2: Passive Shipper SOPs	18
5.2 Monitoring	12	8.3 Case Study 3: Qualification Master Plan.....	20
5.3 Training.....	13	9.0 ADDITIONAL READING	21

FIGURES AND TABLES INDEX

Figure 1.0-1	Qualification Process Flow and Key Deliverables.....	Figure 8.1-1	Deviation Checklist.....
	2		19
Table 3.3-1	Typical Process Parameters for Design Qualification		
	7		



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org